Axsome Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held on June 1, 2018. Axsome Therapeutics, Inc. is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters.
Material Changes and Voting Results
Of the 25,550,492 shares entitled to vote, 21,888,049 shares (approximately 86%) were represented, constituting a quorum. Two proposals were submitted and approved:
- Proposal 1 (Election of Directors): Stockholders elected Herriot Tabuteau, M.D., and Mark Coleman, M.D., as Class III directors. Both received over 11.7 million votes "For" with approximately 840,000 votes "Withheld" each. There were 9,330,255 broker non-votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. The vote was 21,284,957 "For," 585,885 "Against," and 17,207 "Abstaining."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 30, 2018.
Key Facts for Investor Verification
- Verify the full composition of the Board of Directors following the election of the two Class III directors.
- Review the Schedule 14A proxy statement filed on April 30, 2018, for detailed background on the director nominees and auditor ratification.
- Confirm the company's status as an emerging growth company and its election not to use the extended transition period for new accounting standards.